Company intelligence / Profile preview

KPM Tech

Ansan-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~65
Development stage: Other

Overview

KPM Tech is a long-established South Korean company primarily focused on surface treatment chemicals and equipment, with growing interests in pharmaceuticals and biotechnology. Its pharmaceutical division has completed a Phase 1/2a clinical trial in Korea for the investigational pain drug Opiranserin and has partnered to develop and commercialize the monoclonal antibody lenzilumab for COVID-19 in South Korea and the Philippines via licensing from Humanigen[2]. Beyond this, there is no publicly available detailed evidence of late-stage clinical assets or a broad therapeutic pipeline.

Therapeutic areas: Infectious DiseasesNeurology
Modalities: AntibodySmall molecule
Industry: Biotech

Partnerships

Humanigen (lenzilumab licensing/development for COVID-19)Telcon RF Pharmaceutical

Beyond the preview

Go deeper on KPM Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KPM Tech.

Explore the full profile